AXON: Revenue Machine Meets Dilution Problem
Key Takeaways
- Axon grew revenue 32% to $2.78 billion in fiscal 2025, but net income was only $124.9 million due to massive stock-based compensation.
- SBC consumed 20-26% of quarterly revenue, diluting share count by 22.7% in a single year — the biggest risk to per-share returns.
- At 285x trailing PE and $35.1 billion market cap, the stock prices in years of perfect execution with no margin for error.
- The competitive moat is genuine: integrated law enforcement tech stack with high switching costs and government spending tailwinds.
- Hold for existing shareholders; new investors should wait for SBC to trend below 20% of revenue before entering.
Axon Enterprise grew revenue 32% in fiscal 2025 to $2.78 billion. The stock dropped 11.5% after earnings anyway. At $436.53, it trades at 285x trailing earnings — and the earnings themselves are distorted by stock-based compensation that consumed 26% of Q4 revenue.
Axon makes products law enforcement agencies genuinely need: body cameras, Tasers, cloud evidence management. The competitive position is real and the TAM is expanding. But between the SBC dilution, erratic quarterly profitability, and a PE that assumes sustained hypergrowth, this is a stock where the business quality and the investment quality have diverged.
Down 51% from its $885.92 year high, Axon is cheaper than it's been in over a year. The question is whether cheaper is cheap enough.
Valuation: Premium Justified by Growth, Strained by SBC
Axon trades at 285x trailing earnings, 57.3x sales, and 14.1x book value. The EV/EBITDA ratio of 830.7x (see stock valuation metrics) reflects the mismatch between Axon's revenue growth and its bottom-line profitability.
The problem isn't the business — it's the accounting. Stock-based compensation totaled $208.7 million in Q4 alone, or 26.2% of revenue. Across the full year, SBC ranged from 20.6% to 26.2% of quarterly revenue. Strip out SBC and operating income looks far healthier; leave it in and Axon barely breaks even.
At a $35.1 billion market cap on $124.9 million in full-year net income, the math requires either a dramatic SBC reduction or revenue acceleration that outgrows the dilution. Forward estimates project roughly $4.0 EPS by fiscal 2028 — a 109x forward PE at today's price. That's better than 285x, but still priced for perfection.
Earnings: Revenue Surging, Profits Erratic
Fiscal 2025 revenue grew from $603.6 million in Q1 to $796.7 million in Q4 — a 32% sequential improvement and roughly 35% year-over-year growth. Gross margins held steady between 57.9% and 60.6%, demonstrating pricing power and recurring software revenue scaling.
But net income told a different story. Q1 delivered $88.0 million thanks to $116.3 million in other income (likely investment gains). Q2 earned $36.1 million aided by a $75 million tax benefit. Q3 posted a $2.2 million loss. Q4 scraped by with $3.0 million in profit.
The underlying operating income was negative in three of four quarters. Q4's $10.0 million operating income was the only genuinely positive quarter — on $796.7 million in revenue, that's a 1.3% operating margin. SBC is the primary culprit, but R&D spending at 16.8% of revenue also weighs on profitability.
Financial Health: Cash-Rich, SBC-Heavy
Axon's balance sheet is solid. Cash per share stands at $21.23, with total debt of $1.94 billion against $3.24 billion in shareholders' equity (debt/equity: 0.59). The current ratio of 2.53 provides ample liquidity.
Q4 operating cash flow surged to $217.2 million ($2.70/share), the strongest quarter of the year. Free cash flow hit $155.3 million ($1.93/share) after capex — a material improvement over prior quarters where FCF was negative (Q2) or negligible.
The issue remains dilution. Weighted average diluted shares rose from 81.5 million in Q1 to 100.0 million in Q4 — a 22.7% increase in a single year. Every dollar of real earnings is being shared across a rapidly expanding share count.
Competitive Position: Dominant and Expanding
Axon's moat is deep. No competitor matches its integrated ecosystem: Taser hardware, body cameras, Axon Evidence (cloud), Axon Records, and the AI-powered Draft One report-writing tool. Law enforcement agencies that adopt one product typically adopt the full suite, creating high switching costs.
The government and defense tailwind is real. Defender Capital initiated a $23.8 million position in Q4, and Zacks noted Axon posted 36% EBITDA growth with margin expansion year-over-year. The defense and public safety sector is one of the few areas where government spending shows no signs of contraction.
The risk is concentration. Axon depends heavily on U.S. law enforcement budgets, which are subject to political cycles. International expansion and commercial applications (enterprise security) represent the growth optionality, but contribute a minority of current revenue.
Forward Outlook: Growth Priced In, Execution Required
Analyst estimates project quarterly revenue reaching $1.27 billion by Q1 2028, growing to $1.69 billion by Q4 2028. That implies annual revenue of roughly $6.3 billion — more than doubling from 2025's $2.78 billion.
EPS estimates climb from $2.88 in Q1 2028 to $3.98 by Q4 2028, suggesting meaningful operating leverage if SBC moderates as a percentage of revenue. At today's $436.53, that puts the fiscal 2028 forward PE at roughly 110x — still elevated but more defensible than the current 285x.
The next earnings report arrives May 6, 2026. Watch for two things: SBC as a percentage of revenue (needs to trend below 20%) and operating income turning sustainably positive. Without both, the PE contraction thesis doesn't work.
Conclusion
Axon owns one of the best competitive positions in government technology. Revenue growth is exceptional, the product ecosystem is sticky, and the defense spending environment is favorable. On fundamentals alone, this is a hold-quality business.
But the stock is not the business. At 285x earnings with stock-based compensation consuming a quarter of revenue, Axon requires years of perfect execution just to grow into its valuation. The 51% drawdown from $885.92 makes it more interesting than six months ago — but at $436, the risk-reward favors patience. Hold if you own it; wait for a sustained SBC inflection before initiating a new position.
Frequently Asked Questions
Sources & References
www.sec.gov
Disclaimer: This content is for informational purposes only and does not constitute financial advice. Consult qualified professionals before making investment decisions.